Results 301 to 310 of about 287,154 (333)
Some of the next articles are maybe not open access.
Current Opinion in Oncology, 2008
Triple-negative breast cancer has been of great interest to oncologists because these cancers do not benefit from hormonal therapies or treatments targeted against human epidermal growth factor receptor 2 receptors. The only systemic therapy currently available is chemotherapy, and prognosis remains poor.
Gert, Stockmans +4 more
+6 more sources
Triple-negative breast cancer has been of great interest to oncologists because these cancers do not benefit from hormonal therapies or treatments targeted against human epidermal growth factor receptor 2 receptors. The only systemic therapy currently available is chemotherapy, and prognosis remains poor.
Gert, Stockmans +4 more
+6 more sources
Metastatic Triple-negative Breast Cancer
Clinical Oncology, 2011The triple-negative class (oestrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) comprises about 15% of breast cancer. It is associated with a poor prognosis compared with tumours that are positive for hormone receptors or HER2.
E A, Rakha, S, Chan
openaire +2 more sources
DeckerMed CGSO Case-Based Reviews, 2019
Triple-negative breast cancer (TNBC) represents approximately 15% of breast cancers and is characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2). The annual incidence of TNBC is estimated to be approximately 40,000, with 20,000 diagnosed with metastatic ...
Ritika Vankina, Yuan Yuan
openaire +2 more sources
Triple-negative breast cancer (TNBC) represents approximately 15% of breast cancers and is characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2). The annual incidence of TNBC is estimated to be approximately 40,000, with 20,000 diagnosed with metastatic ...
Ritika Vankina, Yuan Yuan
openaire +2 more sources
Advanced Triple-Negative Breast Cancer
Seminars in Oncology NursingOur focus within this review is to summarize key advances and new therapeutic approaches within advanced triple-negative breast cancer. In addition, we highlight the importance of multidisciplinary management, discussing key issues for patients and importance of the supportive role that specialist nurses provide.Peer-reviewed literature, clinical ...
Patel, G, Prince, A, Harries, M
openaire +3 more sources
Epidemiology of triple negative breast cancers [PDF]
Breast Disease, 2011 Triple negative (TN) breast cancers fail to express the three most common breast cancer receptors; i.e., estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). Accumulating data demonstrate that epidemiological risk factor profiles also vary between TN (ER-PR-HER2-) and other breast cancers, especially ...
Gretchen L, Gierach +2 more
openaire +2 more sources
Immunotherapy in Triple-Negative Breast Cancer
The Cancer Journal, 2021Abstract Triple-negative breast cancer (TNBC) is an aggressive subtype of mammary carcinoma. A subset of TNBC is immune activated, suggesting that immunotherapy may be a viable treatment strategy. Phase III clinical trials have shown that atezolizumab or pembrolizumab is well-tolerated in combination with chemotherapy, with progression-free ...
openaire +2 more sources
Triple-negative breast cancers
Expert Review of Anticancer Therapy, 2023Steven A, Narod, Rebecca, Dent
openaire +2 more sources
2016
Breast cancer is a heterogeneous disease consisting of distinct biological subtypes and triple-negative breast cancers (TNBC) are those that lack expression of the breast cancer prognostic markers ER, PR and HER2. TNBC often follows an aggressive disease course with poorer disease-specific survival compared to other breast cancer subtypes.
openaire +1 more source
Breast cancer is a heterogeneous disease consisting of distinct biological subtypes and triple-negative breast cancers (TNBC) are those that lack expression of the breast cancer prognostic markers ER, PR and HER2. TNBC often follows an aggressive disease course with poorer disease-specific survival compared to other breast cancer subtypes.
openaire +1 more source
Less Common Triple-Negative Breast Cancers
2016This chapter encompasses four uncommon types of triple negative breast cancer, which include adenoid cystic carcinoma (ACC), apocrine carcinoma, metaplastic carcinoma, and medullary carcinoma. Also included in the discussion for differential diagnosis are three additional rare subtypes: acinic cell carcinoma, oncocytic carcinoma, and mucoepidermoid ...
Poonam Vohra +2 more
openaire +1 more source